The only once-a-day hydrocodone with FDA-approved abuse-deterrent properties (ADP)¹

Hysingla ER has FDA-approved labeling that describes abuse-deterrent properties based on the results from Category 1 and 3 studies

Formulated with properties intended to:

• Make the tablet more difficult to misuse and abuse
• Maintain some extended-release characteristics if physically compromised

• The in vitro data demonstrate that Hysingla ER has physical and chemical properties that are expected to deter intranasal and intravenous abuse
• The data from the clinical abuse potential studies, along with support from the in vitro data, also indicate that Hysingla ER has physicochemical properties that are expected to reduce intranasal abuse and oral abuse when chewed
• Abuse-deterrent properties do not prevent or reduce the risk of addiction²

• Abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible

• All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use
• With parenteral abuse, the inactive ingredients in Hysingla ER can result in local tissue necrosis, infection, pulmonary granulomas, increased risk of endocarditis and valvular heart injury, embolism, and death. Parenteral drug abuse is commonly associated with transmission of infectious diseases, such as hepatitis and HIV